Biocartis Idylla™ GeneFusion Assay*

Last updated: 09th May, 2024

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.

Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1, RET, NTRK1/2/3 rearrangements and MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections.


DETECTION OF KNOWN AND NOVEL FUSIONS

The new Idylla™ GeneFusion Assay is a unique combination of 2 detection technologies:

  1. Direct Detection: Highly sensitive detection of known fusion isoforms by RT-qPCR of sample RNA.
  2. Expression Imbalance Analysis: Detection of fusion events without knowledge of the fusion partners by analyzing expression ratios between the 5’ and 3’ ends of the gene.

SPECIMEN REQUIREMENTS

One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the Idylla™ system only a minimal amount of sample is needed:

  • If ≥ 20 mm² tissue area -> 1 x 5 μm FFPE tissue section
  • If < 20 mm² tissue area -> 3 x 5 μm FFPE tissue sections
  • ≥ 10% neoplastic cell content

Learn more about Biocartis Idylla GeneFusion

View more on the Idylla GeneFusion Assay

Download Brochure >

Technical Sheet Idylla GeneFusion

Download Here >

Read the Arcila et al 2022 Clinical Utility and Performance of GeneFusion Elsevier article

Download Here >

View the Leone et al 2023 Robust Performance of the Novel RUO GF assay for NSCLC Cancers article

Download Here >

Read the Buglioni et al 2022 Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC IASLC article

Download Here >

*Research use only

 



Request a Quote

Request Quote

Go BackGo Back
Top